Title : Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.

Pub. Date : 2015 Apr

PMID : 25223561






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Therefore, MVK and FDFT1 polymorphisms are genetic determinants for BMD response to alendronate therapy in postmenopausal Chinese women. Alendronate mevalonate kinase Homo sapiens